||Successful Everolimus Treatment of Renal Angiomyolipoma and Lymphangioleiomyomatosis: A Case Report
Naohisa, Urabe ,
Susumu, Sakamoto ,
Yasuhiko, Nakamura ,
Kyoko, Gocho ,
Takao, IshiwatariSakae, Homma
29 , 2016-03 , The Medical Society of Toho University
A 42-year-old woman with renal angiomyolipoma and lymphangioleiomyomatosis associated with tuberous sclerosis complex was treated with the mammalian target of rapamycin (mTOR) inhibitor everolimus. After 6 months of treatment, the maximum size of the renal angiomyolipoma decreased from 58×41 to 37×32 mm on abdominal contrast-enhanced computed tomography (CT). Pulmonary nodules also decreased in size on chest CT. Forced expiratory volume in 1 second (FEV1) decreased from 1740 to 1680 ml, but <GAIJI code=b129/>50/<GAIJI code=b129/>25 ratio improved from 4.38 to 3.58 on pulmonary function testing. Although stomatitis is a known major adverse effect of everolimus treatment, it was mild in severity in the present patient.